Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: LY2127399
Drug: Placebo

First Posted Date: 2008-11-05

Last Posted Date: 2018-07-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 158

Registration Number: NCT00785928

Locations: 🇺🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Simferopol, Ukraine

An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia

Phase 2

Completed

Conditions: Primary Insomnia
Secondary Insomnia

Interventions: Drug: Placebo
Drug: LY2624803
Drug: zolpidem

First Posted Date: 2008-11-04

Last Posted Date: 2012-02-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 643

Registration Number: NCT00784875

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lakewood, Washington, United States

Study of Tadalafil Once-a-Day for 12 Weeks in Japanese Men With Benign Prostatic Hyperplasia Followed by an Open-Label Extension

Phase 2

Completed

Conditions: Benign Prostatic Hyperplasia

Interventions: Drug: Tadalafil 5 mg
Drug: Tadalafil 2.5 mg
Drug: Placebo

First Posted Date: 2008-10-31

Last Posted Date: 2011-03-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 422

Registration Number: NCT00783094

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan

Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Biological: IMC-18F1

First Posted Date: 2008-10-29

Last Posted Date: 2010-09-30

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 27

Registration Number: NCT00782002

Locations: 🇺🇸
ImClone Investigational Site, Cleveland, Ohio, United States

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Phase 2

Completed

Conditions: Carcinoma
Neuroendocrine Tumors

Interventions: Biological: Cixutumumab
Drug: depot octreotide

First Posted Date: 2008-10-29

Last Posted Date: 2019-09-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 43

Registration Number: NCT00781911

Locations: 🇺🇸
ImClone Investigational Site, Dallas, Texas, United States

Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Biological: IMC-3G3

First Posted Date: 2008-10-08

Last Posted Date: 2011-06-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 20

Registration Number: NCT00768391

Locations: 🇺🇸
ImClone Investigational Site, Houston, Texas, United States

A Study for Patient With Chronic Low Back Pain

Phase 3

Completed

Conditions: Chronic Low Back Pain

Interventions: Drug: Placebo
Drug: Duloxetine

First Posted Date: 2008-10-07

Last Posted Date: 2010-10-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 401

Registration Number: NCT00767806

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain

A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel

Phase 2

Withdrawn

Conditions: Lung Neoplasms
Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Cetuximab
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2008-10-07

Last Posted Date: 2015-10-28

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT00768131

Locations: 🇺🇸
Local Institution, Austin, Texas, United States

A Study in the Treatment of Acute Mania

Phase 4

Terminated

Conditions: Bipolar Disorder

Interventions: Drug: olanzapine
Drug: haloperidol
Drug: zuclopentixol

First Posted Date: 2008-10-07

Last Posted Date: 2008-10-07

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 11

Registration Number: NCT00767715

Locations: 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Danderyd, Sweden

A Study of Arzoxifene to Treat Korean Women With Osteoporosis

Phase 2

Completed

Conditions: Osteoporosis

Interventions: Drug: arzoxifene
Drug: Placebo

First Posted Date: 2008-10-07

Last Posted Date: 2015-04-30

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 91

Registration Number: NCT00767299

Locations: 🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy